Cardiol Therapeutics Inc Class A (CRDL) is a Healthcare · Drug Manufacturers - Specialty & Generic company listed on NASDAQ. Price $1.88 (+0.81%), Market cap $0.15B, 52-week low–high $0.93 ~ $1.63.
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
Financial statements, price targets, institutional (13F) holdings and related news for Cardiol Therapeutics Inc Class A are updated in real time on BlackAll Trade.
Cardiol Therapeutics Inc Class A trades at $1.88 (+0.81%). Real-time quotes and charts are available on BlackAll Trade.
Cardiol Therapeutics Inc Class A has a market cap of about $0.15B.
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product can